Biologically, we propose to monitor prothrombin time, APTT, fibrinogen, and D-dimers at least every 48 h, combined in patients treated with UFH with monitoring of platelet count and anti-Xa activity (if curative doses and/or renal failure). This evidence concerns the gene F2 and kidney failure.